drugset / Trial / NCT04675086
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
Phase 3
Withdrawn
Blessing Corporate Services, Inc
Takeda Pharmaceuticals North America, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP Infusion Therapy with Antiviral Treatment and standard of care versus Antiviral Treatment and standard of care (control group) in Hospitalized Patients with Pneumonia and COVID-19 Infection.
Timeline
- Start
- 2021-01
- Primary completion
- 2021-09
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | 60 mg/kg | Intravenous |
| Background | Remdesivir | Small molecule | 100 mg | — |